Atrial Fibrillation Trial, Recruiting NCT06833138 Sponsor: French Cardiology Society Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT06833138
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with permanent atrial fibrillation (an irregular heart rhythm) lasting more than 6 months
  • Your heart's pumping strength is at or above a normal level (at least 50%)
  • You have been hospitalised at least once for heart failure in the past year
  • Your heart failure symptoms are at least moderate, meaning daily activities are somewhat affected
  • You show at least one sign of your heart having difficulty relaxing properly, based on specific heart scan or blood test results (confirm with trial site)
  • The electrical signal in your heart travels at a normal speed (a measurement called QRS is 120 milliseconds or less)
  • Your average heart rate over a 24-hour monitoring period is no more than 110 beats per minute
  • You are 18 years of age or older
  • You are able to understand what the study involves and are willing to give your formal agreement to take part
  • You are covered by a social insurance scheme
  • If you are a woman who could become pregnant, you are using effective contraception and have a negative pregnancy test

Who may not be able to join:

  • You are considered suitable for a procedure to treat your atrial fibrillation using catheters (thin tubes guided into the heart)
  • Your life expectancy is less than 12 months
  • You have severe kidney disease where your kidneys are working very poorly
  • You have severe lung disease, including needing long-term oxygen therapy at home
  • Your Body Mass Index (BMI) is 40 or above (classified as severe obesity)
  • You have been diagnosed with, or are suspected to have, a condition where abnormal material builds up in the heart muscle (such as amyloidosis, sarcoidosis, or Fabry disease)
  • You have a type of thickened heart muscle that blocks blood flow (obstructive hypertrophic cardiomyopathy)
  • You already have an implanted heart device such as a pacemaker, defibrillator, or cardiac resynchronisation device
  • You have another medical reason that requires you to have a pacemaker or defibrillator fitted
  • You are not able to walk or move around for at least half of your waking time
  • You are currently pregnant
  • You are currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Frédéric ANSELME, MD, CHU de Rouen, France

Phone: +33144907033

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
French Cardiology Society
Registry
ClinicalTrials.gov
Start date
10 September 2025
Est. completion
31 May 2029

Where this trial is recruiting

🇧🇪 Belgium 🇫🇷 France

Primary endpoints

Time to the composite of all-cause mortality or hospitalization due to heart failure or intravenous diuretics.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov